Drug-Induced Liver Injury: Mechanism-Informed Prediction in Drug Development

C. Goldring, R. Weaver, B. Kramer, U. Klingmueller, A. Oppelt, B. Van der Water, J. Commandeur, A. Guillouzo, D. Naisbitt, N. French, N. Kitteringham, C. Pridgeon, P. Knolle, J. Sidaway, R. Sison-Young, L. Kamalian, A. Mercer, L. Faulkner, R. Pieters, M. Ingelman-SundbergB. Kevin Park

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

2 Scopus citations


Drug-induced liver injury (DILI) is a significant clinical problem in terms of patient morbidity and mortality and also represents a challenge for the pharmaceutical industry leading to attrition of drugs in development and withdrawal of drugs post-licencing. The Innovative Medicines Initiative MIP-DILI Consortium details in this review the predominant mechanisms underlying DILI in order to help guide the development of physiologically, pharmacologically, and toxicologically relevant in vitro and in vivo DILI models. The overall thesis of this perspective is that only through a more comprehensive understanding of the mechanisms of human DILI will we be able to improve our efforts in the application of more meaningful models in the laboratory and thereby improve human prediction.

Original languageEnglish
Title of host publicationExperimental Adme and Toxicology
PublisherElsevier Inc.
Number of pages22
ISBN (Electronic)9780128032008
ISBN (Print)9780128032015
StatePublished - 3 Jun 2017


  • DILI
  • Drug
  • Endoplasmic reticulum
  • Immune
  • In vitro models
  • Liver
  • Lysosome
  • Mitochondria
  • Modeling
  • Reactive metabolites
  • Toxicity
  • Translation


Dive into the research topics of 'Drug-Induced Liver Injury: Mechanism-Informed Prediction in Drug Development'. Together they form a unique fingerprint.

Cite this